A new Oxford-based drug-discovery company has been launched with the aim of developing targeted therapies for a specific family of blood cancers. Alethiomics was founded by Oxford BRC-supported researchers Professor Adam Mead and Professor Beth Psaila, with support from Oxford University Innovation. Alethiomics aims to apply innovations in single-cell multi-omic analysis to the development of novel … Read more
Oxford Blood Group - Exchange Newsletters and related news
New atlas reveals pre-birth development of blood cells in bone marrow
A new study has provided the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow. The study, published in Nature, is part of the Human Cell Atlas (HCA) initiative to provide comprehensive reference maps of every cell type in the human body. The research team include … Read more
Researchers develop algorithm to diagnose deep vein thrombosis
Researchers are developing an artificial intelligence (AI) algorithm to diagnose deep vein thrombosis (DVT) more quickly and as effectively as traditional radiologist-interpreted diagnostic scans, potentially cutting down long patient waiting lists and avoiding patients unnecessarily receiving drugs to treat DVT when they don’t have it. The study, published in the journal Digital Medicine, is the … Read more
Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients
The COVID-19 pandemic has led to understandable anxiety within the blood cancer community about how their illness may affect their ability to overcome COVID-19 infection. Members of the Oxford Centre for Haematology have led a collaborative research project looking at the response of patients with chronic lymphocytic leukaemia (CLL) who were infected with COVID-19. The … Read more
What Matters Most: A workshop methodology to hear patients’ priorities
Oxford researchers meet patients to discuss new Advanced Cellular Therapies Centre
Oxford researchers have met with members of the Oxford Blood Group to discuss plans for an Advanced Cellular Therapies Centre. Plans for the creation of an Oxford Advanced Cellular Therapies Centre have been supported by NIHR Research Capability Funding. The proposed centre will bring together scientists, state-of-the-art laboratory facilities, and a treatment centre for the … Read more
Oxford Blood Group: Exchange Newsletter Issue 3 vol 1 / June 2019
Patient involvement partnership sets priorities for rare inherited anaemias
On the occasion of Rare Diseases Day, marked every year on the last day of February, we are sharing this article about how patients, carers, clinicians and researchers are collaborating to decide key questions to shape future research into rare forms of anaemia. Patients with anaemia lack red blood cells, or haemoglobin, which means that … Read more
